Command Palette

Search for a command to run...

Clinical Trials · NCT07392151

Reversal to Normoglycemia by Treating Prediabetes

Not Yet RecruitingPhase 3Semaglutide (Investigational)
Phase
Phase 3
Recruitment status
Not Yet Recruiting
Sponsor
Michael Mæng
Enrollment
158
Start date
Feb 2026
Locations
1 site, Denmark
Primary endpoint
Presence of a composite of retinopathy, nephropathy, neuropathy, and MASLD
View Semaglutide compound reference